Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 513

1.

Sphenopalatine Ganglion Block to Treat Shoulder Tip Pain After Thoracic Surgery: Report of 2 Cases.

Grant GJ, Echevarria GC, Lax J, Pass HI, Oshinsky ML.

A A Pract. 2018 Feb 20. doi: 10.1213/XAA.0000000000000746. [Epub ahead of print]

PMID:
29634542
2.

Involvement of Heparanase in the Pathogenesis of Mesothelioma: Basic Aspects and Clinical Applications.

Barash U, Lapidot M, Zohar Y, Loomis C, Moreira A, Feld S, Goparaju C, Yang H, Hammond E, Zhang G, Li JP, Ilan N, Nagler A, Pass HI, Vlodavsky I.

J Natl Cancer Inst. 2018 Mar 21. doi: 10.1093/jnci/djy032. [Epub ahead of print]

PMID:
29579286
3.

Progress in the Management of Malignant Pleural Mesothelioma in 2017.

McCambridge AJ, Napolitano A, Mansfield AS, Fennell DA, Sekido Y, Nowak AK, Reungwetwattana T, Mao W, Pass HI, Carbone M, Yang H, Peikert T.

J Thorac Oncol. 2018 May;13(5):606-623. doi: 10.1016/j.jtho.2018.02.021. Epub 2018 Mar 8. Review.

PMID:
29524617
4.

Summarizing performance for genome scale measurement of miRNA: reference samples and metrics.

Pine PS, Lund SP, Parsons JR, Vang LK, Mahabal AA, Cinquini L, Kelly SC, Kincaid H, Crichton DJ, Spira A, Liu G, Gower AC, Pass HI, Goparaju C, Dubinett SM, Krysan K, Stass SA, Kukuruga D, Van Keuren-Jensen K, Courtright-Lim A, Thompson KL, Rosenzweig BA, Sorbara L, Srivastava S, Salit ML.

BMC Genomics. 2018 Mar 6;19(1):180. doi: 10.1186/s12864-018-4496-1.

5.

Eighth Edition Staging of Thoracic Malignancies: Implications for the Reporting Pathologist.

Nicholson AG, Tsao MS, Travis WD, Patil DT, Galateau-Salle F, Marino M, Dacic S, Beasley MB, Butnor KJ, Yatabe Y, Pass HI, Rusch VW, Detterbeck FC, Asamura H, Rice TW, Rami-Porta R.

Arch Pathol Lab Med. 2018 May;142(5):645-661. doi: 10.5858/arpa.2017-0245-RA. Epub 2018 Feb 26.

PMID:
29480761
6.

Extracellular signal regulated kinase 5 and inflammasome in progression of mesothelioma.

Thompson JK, Shukla A, Leggett AL, Munson PB, Miller JM, MacPherson MB, Beuschel SL, Pass HI, Shukla A.

Oncotarget. 2017 Dec 6;9(1):293-305. doi: 10.18632/oncotarget.22968. eCollection 2018 Jan 2.

7.

Therapeutic potential of targeting S100A11 in malignant pleural mesothelioma.

Sato H, Sakaguchi M, Yamamoto H, Tomida S, Aoe K, Shien K, Yoshioka T, Namba K, Torigoe H, Soh J, Tsukuda K, Tao H, Okabe K, Miyoshi S, Pass HI, Toyooka S.

Oncogenesis. 2018 Jan 24;7(1):11. doi: 10.1038/s41389-017-0017-3.

8.

Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline.

Kindler HL, Ismaila N, Armato SG 3rd, Bueno R, Hesdorffer M, Jahan T, Jones CM, Miettinen M, Pass H, Rimner A, Rusch V, Sterman D, Thomas A, Hassan R.

J Clin Oncol. 2018 May 1;36(13):1343-1373. doi: 10.1200/JCO.2017.76.6394. Epub 2018 Jan 18.

PMID:
29346042
9.

Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancer.

Morris S, Vachani A, Pass HI, Rom WN, Ryden K, Weiss GJ, Hogarth DK, Runger G, Richards D, Shelton T, Mallery DW.

Int J Cancer. 2018 Jun 1;142(11):2355-2362. doi: 10.1002/ijc.31245. Epub 2018 Jan 30.

10.

HSP90 inhibition alters the chemotherapy-driven rearrangement of the oncogenic secretome.

di Martino S, Amoreo CA, Nuvoli B, Galati R, Strano S, Facciolo F, Alessandrini G, Pass HI, Ciliberto G, Blandino G, De Maria R, Cioce M.

Oncogene. 2018 Mar;37(10):1369-1385. doi: 10.1038/s41388-017-0044-8. Epub 2018 Jan 9.

PMID:
29311642
11.

Stage Dependence, Cell-Origin Independence, and Prognostic Capacity of Serum Glycan Fucosylation, β1-4 Branching, β1-6 Branching, and α2-6 Sialylation in Cancer.

Ferdosi S, Rehder DS, Maranian P, Castle EP, Ho TH, Pass HI, Cramer DW, Anderson KS, Fu L, Cole DEC, Le T, Wu X, Borges CR.

J Proteome Res. 2018 Jan 5;17(1):543-558. doi: 10.1021/acs.jproteome.7b00672. Epub 2017 Nov 21.

PMID:
29129073
12.

Prognosis and "granularity": Building on staging foundations?

Pass HI.

J Thorac Cardiovasc Surg. 2018 Jan;155(1):354-355. doi: 10.1016/j.jtcvs.2017.10.032. Epub 2017 Oct 20. No abstract available.

PMID:
29100584
13.

Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.

Romero R, Sayin VI, Davidson SM, Bauer MR, Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A, Sánchez-Rivera FJ, Subbaraj L, Martinez B, Bronson RT, Prigge JR, Schmidt EE, Thomas CJ, Goparaju C, Davies A, Dolgalev I, Heguy A, Allaj V, Poirier JT, Moreira AL, Rudin CM, Pass HI, Vander Heiden MG, Jacks T, Papagiannakopoulos T.

Nat Med. 2017 Nov;23(11):1362-1368. doi: 10.1038/nm.4407. Epub 2017 Oct 2.

14.

Patient-derived xenografts effectively capture responses to oncology therapy in a heterogeneous cohort of patients with solid tumors.

Izumchenko E, Paz K, Ciznadija D, Sloma I, Katz A, Vasquez-Dunddel D, Ben-Zvi I, Stebbing J, McGuire W, Harris W, Maki R, Gaya A, Bedi A, Zacharoulis S, Ravi R, Wexler LH, Hoque MO, Rodriguez-Galindo C, Pass H, Peled N, Davies A, Morris R, Hidalgo M, Sidransky D.

Ann Oncol. 2017 Oct 1;28(10):2595-2605. doi: 10.1093/annonc/mdx416.

PMID:
28945830
15.

A Panel of Novel Detection and Prognostic Methylated DNA Markers in Primary Non-Small Cell Lung Cancer and Serum DNA.

Ooki A, Maleki Z, Tsay JJ, Goparaju C, Brait M, Turaga N, Nam HS, Rom WN, Pass HI, Sidransky D, Guerrero-Preston R, Hoque MO.

Clin Cancer Res. 2017 Nov 15;23(22):7141-7152. doi: 10.1158/1078-0432.CCR-17-1222. Epub 2017 Aug 29.

PMID:
28855354
16.

Lepidic Predominant Pulmonary Lesions (LPL): CT-based Distinction From More Invasive Adenocarcinomas Using 3D Volumetric Density and First-order CT Texture Analysis.

Alpert JB, Rusinek H, Ko JP, Dane B, Pass HI, Crawford BK, Rapkiewicz A, Naidich DP.

Acad Radiol. 2017 Dec;24(12):1604-1611. doi: 10.1016/j.acra.2017.07.008. Epub 2017 Aug 24.

PMID:
28844845
17.

Inhibition of the spindle assembly checkpoint kinase Mps-1 as a novel therapeutic strategy in malignant mesothelioma.

Szymiczek A, Carbone M, Pastorino S, Napolitano A, Tanji M, Minaai M, Pagano I, Mason JM, Pass HI, Bray MR, Mak TW, Yang H.

Oncogene. 2017 Nov 16;36(46):6501-6507. doi: 10.1038/onc.2017.266. Epub 2017 Jul 31.

18.

Diagnostic and prognostic biomarkers for malignant mesothelioma: an update.

Chen Z, Gaudino G, Pass HI, Carbone M, Yang H.

Transl Lung Cancer Res. 2017 Jun;6(3):259-269. doi: 10.21037/tlcr.2017.05.06. Review.

19.

Diagnosis and prognosis-review of biomarkers for mesothelioma.

Sun HH, Vaynblat A, Pass HI.

Ann Transl Med. 2017 Jun;5(11):244. doi: 10.21037/atm.2017.06.60. Review.

20.

Clinical validation of a blood-based classifier for diagnostic evaluation of asymptomatic individuals with pulmonary nodules.

Birse CE, Tomic JL, Pass HI, Rom WN, Lagier RJ.

Clin Proteomics. 2017 Jul 5;14:25. doi: 10.1186/s12014-017-9158-9. eCollection 2017.

21.

Quality Initiatives: Baby Steps in the Right Direction.

Pass HI.

Semin Thorac Cardiovasc Surg. 2017 Spring;29(1):102-103. doi: 10.1053/j.semtcvs.2017.03.005. Epub 2017 Mar 31.

PMID:
28683984
22.

Germline BAP1 mutations induce a Warburg effect.

Bononi A, Yang H, Giorgi C, Patergnani S, Pellegrini L, Su M, Xie G, Signorato V, Pastorino S, Morris P, Sakamoto G, Kuchay S, Gaudino G, Pass HI, Napolitano A, Pinton P, Jia W, Carbone M.

Cell Death Differ. 2017 Oct;24(10):1694-1704. doi: 10.1038/cdd.2017.95. Epub 2017 Jun 30.

23.

Identification of autoantibodies to ECH1 and HNRNPA2B1 as potential biomarkers in the early detection of lung cancer.

Dai L, Li J, Tsay JJ, Yie TA, Munger JS, Pass H, Rom WN, Tan EM, Zhang JY.

Oncoimmunology. 2017 Mar 31;6(5):e1310359. doi: 10.1080/2162402X.2017.1310359. eCollection 2017.

24.

BAP1 regulates IP3R3-mediated Ca2+ flux to mitochondria suppressing cell transformation.

Bononi A, Giorgi C, Patergnani S, Larson D, Verbruggen K, Tanji M, Pellegrini L, Signorato V, Olivetto F, Pastorino S, Nasu M, Napolitano A, Gaudino G, Morris P, Sakamoto G, Ferris LK, Danese A, Raimondi A, Tacchetti C, Kuchay S, Pass HI, Affar EB, Yang H, Pinton P, Carbone M.

Nature. 2017 Jun 22;546(7659):549-553. doi: 10.1038/nature22798. Epub 2017 Jun 14.

25.

Pleural IMRT after Lung-Sparing Cytoreduction for Mesothelioma: Mature Enough to Randomize.

Pass HI.

J Thorac Oncol. 2017 Jun;12(6):919-921. doi: 10.1016/j.jtho.2017.04.013. No abstract available.

PMID:
28532562
26.

Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.

Kris MG, Gaspar LE, Chaft JE, Kennedy EB, Azzoli CG, Ellis PM, Lin SH, Pass HI, Seth R, Shepherd FA, Spigel DR, Strawn JR, Ung YC, Weyant M.

J Clin Oncol. 2017 Sep 1;35(25):2960-2974. doi: 10.1200/JCO.2017.72.4401. Epub 2017 Apr 24. Review.

PMID:
28437162
27.

Influence of Extent of Lymph Node Evaluation on Survival for Pathologically Lymph Node Negative Non-Small Cell Lung Cancer.

Becker DJ, Levy BP, Gold HT, Sherman SE, Makarov DV, Schreiber D, Wisnivesky JP, Pass HI.

Am J Clin Oncol. 2017 Mar 15. doi: 10.1097/COC.0000000000000379. [Epub ahead of print]

PMID:
28301349
28.

FTY720 inhibits mesothelioma growth in vitro and in a syngeneic mouse model.

Szymiczek A, Pastorino S, Larson D, Tanji M, Pellegrini L, Xue J, Li S, Giorgi C, Pinton P, Takinishi Y, Pass HI, Furuya H, Gaudino G, Napolitano A, Carbone M, Yang H.

J Transl Med. 2017 Mar 15;15(1):58. doi: 10.1186/s12967-017-1158-z.

29.

Introduction: Great Institutions in Cardiothoracic Surgery, Second Edition.

Rosengart TK, Austin EH, Pass HI, Weisel RD.

Semin Thorac Cardiovasc Surg. 2016 Autumn;28(3):609-610. doi: 10.1053/S1043-0679(17)30038-2. No abstract available.

PMID:
28285664
30.

HMGB1 targeting by ethyl pyruvate suppresses malignant phenotype of human mesothelioma.

Pellegrini L, Xue J, Larson D, Pastorino S, Jube S, Forest KH, Saad-Jube ZS, Napolitano A, Pagano I, Negi VS, Bianchi ME, Morris P, Pass HI, Gaudino G, Carbone M, Yang H.

Oncotarget. 2017 Apr 4;8(14):22649-22661. doi: 10.18632/oncotarget.15152.

31.

Integrated Metabolomics and Proteomics Highlight Altered Nicotinamide- and Polyamine Pathways in Lung Adenocarcinoma.

Fahrmann JF, Grapov DD, Wanichthanarak K, DeFelice BC, Salemi MR, Rom WN, Gandara DR, Phinney BS, Fiehn O, Pass H, Miyamoto S.

Carcinogenesis. 2017 Jan 3. pii: bgw205. doi: 10.1093/carcin/bgw205. [Epub ahead of print] Review.

32.

Improving the Accuracy of Mesothelioma Diagnosis in China.

Guo Z, Carbone M, Zhang X, Su D, Sun W, Lou J, Gao Z, Shao D, Chen J, Zhang G, Hu J, Chen K, Wang F, Pass HI, Yu H, Napolitano A, Yang H, Mao W.

J Thorac Oncol. 2017 Apr;12(4):714-723. doi: 10.1016/j.jtho.2016.12.006. Epub 2016 Dec 19.

33.

Association of Asbestos Exposure With Malignant Mesothelioma Incidence in Eastern China.

Mao W, Zhang X, Guo Z, Gao Z, Pass HI, Yang H, Carbone M.

JAMA Oncol. 2017 Apr 1;3(4):562-564. doi: 10.1001/jamaoncol.2016.5487. No abstract available.

34.

Long-Term Update of NRG Oncology RTOG 0319: A Phase 1 and 2 Trial to Evaluate 3-Dimensional Conformal Radiation Therapy Confined to the Region of the Lumpectomy Cavity for Stage I and II Breast Carcinoma.

Rabinovitch R, Moughan J, Vicini F, Pass H, Wong J, Chafe S, Petersen I, Arthur DW, White J.

Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1054-1059. doi: 10.1016/j.ijrobp.2016.08.042. Epub 2016 Sep 3.

35.

High-density array-CGH with targeted NGS unmask multiple noncontiguous minute deletions on chromosome 3p21 in mesothelioma.

Yoshikawa Y, Emi M, Hashimoto-Tamaoki T, Ohmuraya M, Sato A, Tsujimura T, Hasegawa S, Nakano T, Nasu M, Pastorino S, Szymiczek A, Bononi A, Tanji M, Pagano I, Gaudino G, Napolitano A, Goparaju C, Pass HI, Yang H, Carbone M.

Proc Natl Acad Sci U S A. 2016 Nov 22;113(47):13432-13437. Epub 2016 Nov 9.

36.

Proteomic profiling of lung adenocarcinoma indicates heightened DNA repair, antioxidant mechanisms and identifies LASP1 as a potential negative predictor of survival.

Fahrmann JF, Grapov D, Phinney BS, Stroble C, DeFelice BC, Rom W, Gandara DR, Zhang Y, Fiehn O, Pass H, Miyamoto S.

Clin Proteomics. 2016 Oct 27;13:31. doi: 10.1186/s12014-016-9132-y. eCollection 2016.

37.

The IASLC Mesothelioma Staging Project: Improving Staging of a Rare Disease Through International Participation.

Pass H, Giroux D, Kennedy C, Ruffini E, Cangir AK, Rice D, Asamura H, Waller D, Edwards J, Weder W, Hoffmann H, van Meerbeeck JP, Nowak A, Rusch VW; IASLC Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions.

J Thorac Oncol. 2016 Dec;11(12):2082-2088. doi: 10.1016/j.jtho.2016.09.123. Epub 2016 Sep 23. Review.

38.

Investigating palygorskite's role in the development of mesothelioma in southern Nevada: Insights into fiber-induced carcinogenicity.

Larson D, Powers A, Ambrosi JP, Tanji M, Napolitano A, Flores EG, Baumann F, Pellegrini L, Jennings CJ, Buck BJ, McLaurin BT, Merkler D, Robinson C, Morris P, Dogan M, Dogan AU, Pass HI, Pastorino S, Carbone M, Yang H.

J Toxicol Environ Health B Crit Rev. 2016;19(5-6):213-230.

39.

The IASLC Mesothelioma Staging Project: Proposals for Revisions of the N Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.

Rice D, Chansky K, Nowak A, Pass H, Kindler H, Shemanski L, Opitz I, Call S, Hasegawa S, Kernstine K, Atinkaya C, Rea F, Nafteux P, Rusch VW; Mesothelioma Domain of the IASLC Staging and Prognostic Factors Committee, advisory boards and participating institutions.

J Thorac Oncol. 2016 Dec;11(12):2100-2111. doi: 10.1016/j.jtho.2016.09.121. Epub 2016 Sep 26.

40.

The IASLC Mesothelioma Staging Project: Proposals for Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Pleural Mesothelioma.

Nowak AK, Chansky K, Rice DC, Pass HI, Kindler HL, Shemanski L, Billé A, Rintoul RC, Batirel HF, Thomas CF, Friedberg J, Cedres S, de Perrot M, Rusch VW; Staging and Prognostic Factors Committee, Advisory Boards and Participating Institutions.

J Thorac Oncol. 2016 Dec;11(12):2089-2099. doi: 10.1016/j.jtho.2016.08.147. Epub 2016 Sep 26.

41.

The IASLC Mesothelioma Staging Project: Proposals for the M Descriptors and for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Mesothelioma.

Rusch VW, Chansky K, Kindler HL, Nowak AK, Pass HI, Rice DC, Shemanski L, Galateau-Sallé F, McCaughan BC, Nakano T, Ruffini E, van Meerbeeck JP, Yoshimura M; IASLC Staging and Prognostic Factors Committee, advisory boards, and participating institutions.

J Thorac Oncol. 2016 Dec;11(12):2112-2119. doi: 10.1016/j.jtho.2016.09.124. Epub 2016 Sep 28.

42.

A Multicenter Study of Volumetric Computed Tomography for Staging Malignant Pleural Mesothelioma.

Rusch VW, Gill R, Mitchell A, Naidich D, Rice DC, Pass HI, Kindler HL, De Perrot M, Friedberg J; Malignant Mesothelioma Volumetric CT Study Group.

Ann Thorac Surg. 2016 Oct;102(4):1059-66. doi: 10.1016/j.athoracsur.2016.06.069. Epub 2016 Sep 2.

43.

The Next Generation of Mesothelioma Surgeons Roundtable Discussion.

Pass H, Rice D, Wolf A, Friedberg J, Vigneswaran W.

Semin Thorac Cardiovasc Surg. 2016 Spring;28(1):203-20. doi: 10.1053/j.semtcvs.2016.04.001. Epub 2016 Apr 14. No abstract available.

PMID:
27568163
44.

Autoantibodies against tumor-associated antigens in the early detection of lung cancer.

Dai L, Tsay JC, Li J, Yie TA, Munger JS, Pass H, Rom WN, Zhang Y, Tan EM, Zhang JY.

Lung Cancer. 2016 Sep;99:172-9. doi: 10.1016/j.lungcan.2016.07.018. Epub 2016 Jul 18.

PMID:
27565936
45.

Inhibition of the colony-stimulating-factor-1 receptor affects the resistance of lung cancer cells to cisplatin.

Pass HI, Lavilla C, Canino C, Goparaju C, Preiss J, Noreen S, Blandino G, Cioce M.

Oncotarget. 2016 Aug 30;7(35):56408-56421. doi: 10.18632/oncotarget.10895.

46.

Consensus Report of the 2015 Weinman International Conference on Mesothelioma.

Carbone M, Kanodia S, Chao A, Miller A, Wali A, Weissman D, Adjei A, Baumann F, Boffetta P, Buck B, de Perrot M, Dogan AU, Gavett S, Gualtieri A, Hassan R, Hesdorffer M, Hirsch FR, Larson D, Mao W, Masten S, Pass HI, Peto J, Pira E, Steele I, Tsao A, Woodard GA, Yang H, Malik S.

J Thorac Oncol. 2016 Aug;11(8):1246-1262. doi: 10.1016/j.jtho.2016.04.028.

47.

Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma.

Carbone M, Shimizu D, Napolitano A, Tanji M, Pass HI, Yang H, Pastorino S.

Oncotarget. 2016 Sep 13;7(37):59314-59321. doi: 10.18632/oncotarget.10653.

48.

Extracellular mRNA Detected by Tethered Lipoplex Nanoparticle Biochip for Lung Adenocarcinoma Detection.

Lee LJ, Yang Z, Rahman M, Ma J, Kwak KJ, McElroy J, Shilo K, Goparaju C, Yu L, Rom W, Kim TK, Wu X, He Y, Wang K, Pass HI, Nana-Sinkam SP.

Am J Respir Crit Care Med. 2016 Jun 15;193(12):1431-3. doi: 10.1164/rccm.201511-2129LE. No abstract available.

49.

Computed Tomography Screening for Lung Cancer: Mediastinal Lymph Node Resection in Stage IA Nonsmall Cell Lung Cancer Manifesting as Subsolid and Solid Nodules.

Flores RM, Nicastri D, Bauer T, Aye R, Andaz S, Kohman L, Sheppard B, Mayfield W, Thurer R, Korst R, Straznicka M, Grannis F, Pass H, Connery C, Yip R, Smith JP, Yankelevitz DF, Henschke CI, Altorki NK; Writing committee for the I-ELCAP Investigators.

Ann Surg. 2017 May;265(5):1025-1033. doi: 10.1097/SLA.0000000000001802.

PMID:
27232256
50.

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.

Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR.

J Thorac Oncol. 2016 Jul;11(7):946-63. doi: 10.1016/j.jtho.2016.05.008. Epub 2016 May 23. Review.

Supplemental Content

Support Center